|
|
 |
|
Viewing report
|
|
|
|
Triple Analysis: Decoding Big Pharma's R&D Strategy In Oncology and Special Focus on Breast and Prostate Cancer
Bioseeker, Sep 2007, Pages: 445
This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the breast- and prostate cancer field. This extensive 440+ pages report compiles and analyzes Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.
The collective force of the above research and analysis ’decodes’ these five big pharma R&D efforts into strategy revealing and gap filing presentations. Enough to fuel and sustain comparative benchmarking, peer group surveillance, and partnership decisions.
The report further gives an in depth analysis in two important key oncology areas; Breast- and Prostate cancer . And provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
Decoding Big Pharma’s R&D Strategy in Oncology in numbers:
- Includes references to more than 250 drugs and 600 clinical/preclinical trials
- Addresses the competitive situation on more than 80 different cancer indications, including supportive care indications
- Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase inhibitor- and Vaccine drugs for the treatment of cancer
- The included competitive landscape between the five big pharma includes more than 200 companies related to cancer drug development
- Last five years of deals and alliances in oncology, including almost a hundred different key deals and alliances
- Target analysis of 119 drug targets in oncology, including molecular function of target, target localization, type of compound for targeting, targets affecting signaling pathways etc
- Drug compound analysis by cancer indications
In breast cancer we have identified 170 drug candidates in clinical stage of development and more than 100 companies are involved in the development of these drugs. As a treatment for breast cancer hormone modifying therapies together with different chemotherapeutic schedules have been of highest interest during the last years of progress. A vast amount of new clinical research data has emerged and several new clinical trials have been initiated and others generated new results. Protein kinase inhibitors and epothilones have generated substantial amount of new research data in this field. But, other strategies seem not successful and we are still waiting new information regarding their progress.
In prostate cancer we have identified 127 drug candidates in phase II or III stage of development and more than 85 companies are involved in the development of these drugs. Two of the most successful strategies are apoptosis inducers and cell based vaccines. Three out of 10 late stage candidates are apoptosis inducers. Cell based vaccines has been tried for some time but has so far failed to generate substantial improvements.
Breast and Prostate Cancer Highlights
- Thorough examination of status and impact of several novel drugs in development
- Discussion of the challenges in current and future treatment strategies
- Anticancer pipeline of most companies in the field
Key reasons to read this report
- This report serves as a serious reference for professionals interested in the development of oncology drug targets and selection/validation of targeting strategies.
- Explore the strengths and weaknesses associated with compounds in clinical development.
- Scientific rationale for most novel therapeutics in breast- and prostate cancer R&D, and the results of clinical trials to date
- Gain insight into the current challenges and commercial opportunities associated with breast- and prostate cancer therapy
Customers who bought this item also bought
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Antibody Drug Targets and Focus on Breast & Prostate Cancer
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus Lung Cancer and Melanoma
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas
Prostate and Breast Cancer- New Treatments & Developmental Progress
Cancer Drug Discoveries: What the Future Holds: Prostate Cancer Chapter
Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis
Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis
Drug Targets for Breast Cancer
Prostate Cancer - A Therapeutic & Competitive Insight
|
|
|
|
